# Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

> **NCT02120469** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 27 (actual)

## Conditions studied

- Estrogen Receptor Negative
- HER2/Neu Negative
- Progesterone Receptor-negative
- Stage IV Breast Cancer
- Triple-negative Breast Carcinoma

## Interventions

- **DRUG:** everolimus
- **DRUG:** eribulin mesylate
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02120469
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-01
- **Primary completion:** 2019-03-20
- **Final completion:** 2020-03-03
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2022-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02120469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02120469, "Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02120469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*